sorafenib

Known as: 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate, 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide, SFN 
A drug used to treat advanced kidney cancer and a type of liver cancer that cannot be removed by surgery. It is also being studied in the treatment… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Hepatocellular carcinoma is the sixth most prevalent cancer and the third most frequent cause of cancer-related death. Patients… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND & AIMS The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Most cases of hepatocellular carcinoma occur in the Asia-Pacific region, where chronic hepatitis B infection is an… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE Mature survival data and evaluation of vascular endothelial growth factor (VEGF) as a prognostic biomarker from the… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study… (More)
  • figure 1
  • table 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Given the molecular pathophysiology of thyroid cancer and the spectrum of kinases inhibited by sorafenib, including Raf… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2006
Highly Cited
2006
PURPOSE This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases… (More)
  • table 2
  • table 1
  • table 3
  • table 4
  • figure 2
Is this relevant?
Review
2006
Review
2006
Since the molecular revolution of the 1980s, knowledge of the aetiology of cancer has increased considerably, which has led to… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
The effects of sorafenib – an oral multikinase inhibitor targeting the tumour and tumour vasculature – were evaluated in patients… (More)
  • table 1
  • table 2
  • figure 1
Is this relevant?